BibTex RIS Cite

The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin

Year 2012, , 121 - 123, 01.09.2012
https://doi.org/10.5799/ahinjs.02.2012.03.0056

Abstract

Hayati Demiraslan, Zeynep Ture, Aysegul Ulu Kılıc The pegylated interferon alpha and ribavirin treatment is well established therapy for hepatitis C virus (HCV) infection. During the treatment alanine aminotransferase (ALT) lare may be observed rarely. A 51-year-old female receiving pegylated interferon and ribavirin therapy for HCV infection, complained nausea, vomit- ing in seventh week of the therapy, and her ALT level was detected over 20 times above the normal level. Hepatitis B sur- face antigen, anti-nuclear antibody, anti-mitochondrial antibody, anti-double stranded DNA antibody and anti-hepatitis A virus IgM antibody were negative, and thyroid stimulating hormone was normal. HCV RNA level was 424 IU/ml. PEG IFN and ribavirin therapy was interrupted for three weeks, after liver enzyme level was detected less than 100U/L, the treatment was resumed. The patient was followed up for 2 months, ALT lare was not observed. In conclusion, we present a rare case with ALT lare, while receiving pegylated interferon and ribavirin therapy for chronic HCV infection.

References

  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis c virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60.
  • Calvaruso V, Craxi A. 2011 European Association of The Study of The Liver Hepatitis C Virus Clinical Practice Guidelines. Liver Int 2012; 32 Suppl 1:2-8.
  • Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hep- atology 2009; 49:1335-1374.
  • Amarapurkar DN. Flares on and off therapy during chronic hbv infection: Pathogenesis, significance and management. Hep B Annual 2008;5:12-22.
  • Demiraslan H, Aygen B, Yildiz O, Soyuer I, Gokahmetoglu S. Kronik hepatit C tedavisinde interferon-α 2a+ ribavirin ile peginterferon-α 2a ribavirin kombinasyonlarının karşılaştırıl- ması. Viral Hepatit Dergisi 2008;13:12-22.
  • Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis b patients induced by the host or the virus? Re- lation to treatment response during peg-interferon alpha-2b therapy. Gut 2005;54:1604-1609.
  • Parana R, Schinoni MI, de Freitas LA, et al. Anti-golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int 2006;26:1148-1154.
  • Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.
  • Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: A case report. Dig Dis Sci 2009; 54:1369-1372.

The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin

Year 2012, , 121 - 123, 01.09.2012
https://doi.org/10.5799/ahinjs.02.2012.03.0056

Abstract

References

  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis c virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60.
  • Calvaruso V, Craxi A. 2011 European Association of The Study of The Liver Hepatitis C Virus Clinical Practice Guidelines. Liver Int 2012; 32 Suppl 1:2-8.
  • Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hep- atology 2009; 49:1335-1374.
  • Amarapurkar DN. Flares on and off therapy during chronic hbv infection: Pathogenesis, significance and management. Hep B Annual 2008;5:12-22.
  • Demiraslan H, Aygen B, Yildiz O, Soyuer I, Gokahmetoglu S. Kronik hepatit C tedavisinde interferon-α 2a+ ribavirin ile peginterferon-α 2a ribavirin kombinasyonlarının karşılaştırıl- ması. Viral Hepatit Dergisi 2008;13:12-22.
  • Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis b patients induced by the host or the virus? Re- lation to treatment response during peg-interferon alpha-2b therapy. Gut 2005;54:1604-1609.
  • Parana R, Schinoni MI, de Freitas LA, et al. Anti-golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int 2006;26:1148-1154.
  • Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.
  • Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: A case report. Dig Dis Sci 2009; 54:1369-1372.
There are 9 citations in total.

Details

Primary Language English
Journal Section Case Report
Authors

Hayati Demiraslan This is me

Zeynep Ture This is me

Aysegul Ulu Kılıc This is me

Publication Date September 1, 2012
Published in Issue Year 2012

Cite

APA Demiraslan, H., Ture, Z., & Kılıc, A. U. (2012). The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. Journal of Microbiology and Infectious Diseases, 2(03), 121-123. https://doi.org/10.5799/ahinjs.02.2012.03.0056
AMA Demiraslan H, Ture Z, Kılıc AU. The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. J Microbil Infect Dis. September 2012;2(03):121-123. doi:10.5799/ahinjs.02.2012.03.0056
Chicago Demiraslan, Hayati, Zeynep Ture, and Aysegul Ulu Kılıc. “The Acute Hepatic Flare in a Patient With Chronic Hepatitis C Infection Receiving Pegylated Interferon Alpha 2b and Ribavirin”. Journal of Microbiology and Infectious Diseases 2, no. 03 (September 2012): 121-23. https://doi.org/10.5799/ahinjs.02.2012.03.0056.
EndNote Demiraslan H, Ture Z, Kılıc AU (September 1, 2012) The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. Journal of Microbiology and Infectious Diseases 2 03 121–123.
IEEE H. Demiraslan, Z. Ture, and A. U. Kılıc, “The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin”, J Microbil Infect Dis, vol. 2, no. 03, pp. 121–123, 2012, doi: 10.5799/ahinjs.02.2012.03.0056.
ISNAD Demiraslan, Hayati et al. “The Acute Hepatic Flare in a Patient With Chronic Hepatitis C Infection Receiving Pegylated Interferon Alpha 2b and Ribavirin”. Journal of Microbiology and Infectious Diseases 2/03 (September 2012), 121-123. https://doi.org/10.5799/ahinjs.02.2012.03.0056.
JAMA Demiraslan H, Ture Z, Kılıc AU. The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. J Microbil Infect Dis. 2012;2:121–123.
MLA Demiraslan, Hayati et al. “The Acute Hepatic Flare in a Patient With Chronic Hepatitis C Infection Receiving Pegylated Interferon Alpha 2b and Ribavirin”. Journal of Microbiology and Infectious Diseases, vol. 2, no. 03, 2012, pp. 121-3, doi:10.5799/ahinjs.02.2012.03.0056.
Vancouver Demiraslan H, Ture Z, Kılıc AU. The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. J Microbil Infect Dis. 2012;2(03):121-3.